Home
Pentixapharm

Pentixapharm Market Share Analysis for May 2026

Ad hoc announcement pursuant to Art. 17 MAR / Section 15 WpHG Clinical pipeline to be refocused on theranostic precision oncology opportunities to enhance value proposition of lead assets The PTF301 diagnostic trial in Marginal Zone Lymphoma (MZL) will be discontinued. New CXCR4 trials in

Industry: N/A

Domainpentixapharm.com

Year Founded2020

Employees51 - 200

Annual Revenue--

Pentixapharm

Pentixapharm (including company regionals)

pentixapharm.com

See more website traffic and engagement information

Total visits to Pentixapharm's top domains

Understand Pentixapharm market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

pentixapharm.com1.2K

See more with Sales Intelligence

Avg. visit duration in Pentixapharm's top domains

Analyze Pentixapharm engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

pentixapharm.com00:00:22

See more with Sales Intelligence

Avg. pageviews on Pentixapharm's top domains

See how Pentixapharm keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

pentixapharm.com1.53

See more with Sales Intelligence

Pentixapharm top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Pentixapharm

These are the website technologies, by industry, used by Pentixapharm top domains

Payment & Currencies (3)

Cart Functionality

Conversion & Analytics (2)

Datadog

eCommerce (2)

Swap

Comments System (1)

Disqus

More Technologies

7

See all

News & Signals from Pentixapharm

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsPentixaPharm GmbH attended event Annual Congress of the European Association of Nuclear Medicine (EANM 2025 on Oct 6th '25.Berlin, Germany, October 6, 2025 - Pentixapharm Holding AG (Frankfurt Prime Standard: PTP), an advanced clinical-stage biotech developing novel radiopharmaceuticals, today announced the presentation of extensive clinical data from independent investigator-initiated studies assessing Pentixapharm's CXCR4-targeting diagnostic lead candidate, [[68] Ga]Ga-PentixaFor, at the ongoing Annual Congress of the European Association of Nuclear Medicine (EANM 2025) in Barcelona, Spain.

NewsPentixaPharm GmbH received financing of $6.98M on Jan 7th '25.BERLIN, Jan. 07, 2025 (GLOBE NEWSWIRE) - Pentixapharm AG, a developer of innovative radiopharmaceuticals, receives 6.77 million Euro for intangible assets formerly developed by Glycotope from undisclosed Asian pharma and biotech companies.

NewsPentixaPharm GmbH received financing of $22M in initial public stock offering on Oct 1st '24.Germany-based radiopharmaceutical firm Pentixapharm has raised nearly $22 million (USD) through an initial public stock offering, the company announced Oct. 1.